| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Baricitinib |
| Brand | Olumiant® |
| Indication | Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate. |
| Assessment Process | |
| Rapid review commissioned | 14/06/2017 |
| Rapid review completed | 13/07/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations November 2017
